Rhabdoid Tumor Predisposition Syndrome
Symptoms, Doctors, Treatments, Advances & More

Save information for later
Sign Up

Learn About Rhabdoid Tumor Predisposition Syndrome

What is the definition of Rhabdoid Tumor Predisposition Syndrome?
Limb-girdle muscular dystrophy type 2A (LGMD2A) is an autosomal recessive limb-girdle muscular dystrophy characterized by progressive, symmetrical weakness of the proximal limb and girdle muscles (mainly those around the hips and shoulders) without heart involvement or intellectual disability. The condition is caused by genetic changes in the CAPN3 gene. Type 2A is the most common form of limb-girdle muscular dystrophy, accounting for about 30 percent of cases. LGMD2A is also known as primary calpainopathy. Calpainopathies are diseases caused by genetic changes in the CAPN3 gene and can be autosomal recessive or autosomal dominant. Pelvifemoral limb-girdle muscular dystrophy (also known as Leyden-Mobius LGMD) is the most frequently observed subtype. In these cases, muscle weakness is first evident in the pelvic girdle and later in the shoulder girdle. In most cases, muscle weakness is first evident in the shoulder girdle and later in the pelvic girdle; HyperCKemia is usually observed in children or young individuals. In most cases, those affected do not have symptoms, just high levels of creatine kinase in their blood.
What are the alternative names for Rhabdoid Tumor Predisposition Syndrome?
  • Limb-girdle muscular dystrophy type 2A
  • Muscular dystrophy limb girdle type 2A, Erb type
  • Calpainopathy
  • LGMD2
  • LGMD2A
  • Leyden-Moebius muscular dystrophy
  • Limb-girdle muscular dystrophy type 2
  • Muscular dystrophy, pelvofemoral
Who are the top Rhabdoid Tumor Predisposition Syndrome Local Doctors?
Distinguished in Rhabdoid Tumor Predisposition Syndrome
Distinguished in Rhabdoid Tumor Predisposition Syndrome

Orthopaedics Clinic At Lauritzen Outpatient Center

4014 Leavenworth St., 
Omaha, NE 
Experience:
28+ years
Languages Spoken:
English

Sean Mcgarry is an Orthopedics provider practicing medicine in Omaha, Nebraska. He has been practicing medicine for over 28 years. Dr. Mcgarry is rated as a Distinguished provider by MediFind in the treatment of Rhabdoid Tumor Predisposition Syndrome. He is also highly rated in 21 other conditions, according to our data. His clinical expertise encompasses Adult Soft Tissue Sarcoma, Bone Tumor, Osteosarcoma, Myxoid Liposarcoma, and Hip Replacement.

Advanced in Rhabdoid Tumor Predisposition Syndrome
Hematology | Oncology
Advanced in Rhabdoid Tumor Predisposition Syndrome
Hematology | Oncology

Advocate Lutheran General Cancer Institute

1700 Luther Ln 1st & 2nd Fl, 
Park Ridge, IL 
Languages Spoken:
English

Pamela Kaiser is a Hematologist and an Oncologist practicing medicine in Park Ridge, Illinois. Dr. Kaiser is rated as an Advanced provider by MediFind in the treatment of Rhabdoid Tumor Predisposition Syndrome. She is also highly rated in 21 other conditions, according to our data. Her clinical expertise encompasses Angiosarcoma, Breast Cancer, Paget Disease of the Breast, Inflammatory Breast Cancer, and Endoscopy. Dr. Kaiser is board certified in American Board Of Internal Medicine, Medical Oncology.

 
 
 
 
Learn about our expert tiers
Learn More
Advanced in Rhabdoid Tumor Predisposition Syndrome
Advanced in Rhabdoid Tumor Predisposition Syndrome

Aurora Orthopedics

2801 W Kinnickinnic River Pkwy, Ste 370, 
Milwaukee, WI 
Languages Spoken:
English

Nicholas Webber is an Orthopedics provider practicing medicine in Milwaukee, Wisconsin. Dr. Webber is rated as an Advanced provider by MediFind in the treatment of Rhabdoid Tumor Predisposition Syndrome. He is also highly rated in 30 other conditions, according to our data. His clinical expertise encompasses Osteoarthritis, Osteonecrosis, Rhabdomyosarcoma Embryonal, Hip Replacement, and Knee Replacement. Dr. Webber is board certified in American Board Of Orthopaedic Surgery.

What are the latest Rhabdoid Tumor Predisposition Syndrome Clinical Trials?
Match to trials
Find the right clinical trials for you in under a minute
Get started
Who are the sources who wrote this article ?

Published Date: May 02, 2022
Published By: Genetic and Rare Diseases Informnation Center